Combined surgery enables better graft fixation

Article

A stable IOL, decreased pseudophacodonesis and improved graft fixation are the benefits of combining Descemet membrane endothelial keratoplasty with glued intrascleral haptic fixation of a posterior-chamber IOL in patients with aphakic or pseudophakic bullous keratopathy, according to recently published research.

A stable IOL, decreased pseudophacodonesis and improved graft fixation are the benefits of combining Descemet membrane endothelial keratoplasty with glued intrascleral haptic fixation of a posterior-chamber IOL in patients with aphakic or pseudophakic bullous keratopathy, according to recently published research.

The researchers base their conclusions on a study of 6 patients who had corneal decompensation and inadequate capsular support requiring implantation/exchange of an IOL; all underwent the single-staged procedure at a tertiary care centre. The investigators injected air during surgery to judge the stability of the anterior chamber and structure of the iris diaphragm–IOL complex. They performed iridoplasties in two of the patients. They observed patients after surgery.

Regarding other complications, 1 patient had a partial graft detachment that had to be re-bubbled, and 1 patient had a small peripheral detachment that spontaneously resolved. The graft remained attached in all patients.

Visual acuity (VA) improved in all patients and corrected distance VA significantly changed following surgery. Mean preoperative corrected distance VA was 0.11 ± 0.07, and mean postoperative corrected distance VA was 0.7 ± 0.17.

The mean postoperative endothelial cell density at 6 months was 1710.3 ± 205.8 cells/mm2.

To read the abstract of the study, go to the Journal of Refractive Surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.